Saturday 17 October 2026
Export BMRA’s income statement to Excel — free account
Biomerica, Inc.
BMRA Healthcare Medical Devices
Biomerica, Inc.’s revenue for fiscal 2026 (year ended May 2026) was $4.5 million, down 16.2% from fiscal 2025. In the quarter to May 2026, revenue grew 17.0%, EPS grew 37.8% and free cash flow fell 35.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
1.85
0.03
−1.60%
Follow BMRA
| May '26 | Feb '26 | Nov '25 | Aug '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.54 | 1.41 | 1.47 | 1.62 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(7.54) | (4.89) | (6.63) | (29.54) | |
P/B ratio |
2.62 | 1.84 | 1.48 | 1.54 | |
Price to Tangible BV |
2.84 | 1.98 | 1.56 | 1.61 | |
EV/Sales |
1.25 | 1.10 | 0.90 | 1.00 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.63) | (1.51) | (1.36) | (1.76) | |
EV/FCF |
(1.60) | (1.46) | (1.32) | (1.70) | |
Quick Ratio |
0.84 | 1.46 | 2.18 | 2.52 | |
Current Ratio |
1.62 | 2.64 | 3.25 | 3.48 | |
Net Debt/EBITDA |
0.92 | 1.12 | 2.00 | 3.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.70 | 0.71 | 0.67 | 0.66 | |
Operating CF/Net income |
0.80 | 0.95 | 0.75 | (134.00) | |
Capex/Depreciation |
0.16 | (0.18) | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
23.40% | 18.03% | 15.95% | 15.36% | |
Selling, General and Administrative Expense of Revenue |
143.49% | 109.02% | 101.74% | 96.38% | |
Intangible Assets out of Total Assets |
0.03 | 0.05 | 0.04 | 0.03 | |
Share Based Compensation of Revenue |
10.39% | 13.68% | 9.67% | 9.64% | |
Graham Net Nets |
(0.02) | 0.42 | 0.55 | 0.53 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(53.78%) | (73.87%) | (68.12%) | (52.32%) | |
Free Cash Flow Yield |
(50.54%) | (53.64%) | (46.47%) | (36.05%) | |
Revenue per Share |
0.30 | 0.33 | 0.42 | 0.52 | |
Operating CF per Share |
(0.31) | (0.42) | (0.34) | (0.10) | |
Capex per Share |
0.01 | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.31) | (0.42) | (0.34) | (0.10) | |
Cash per Share |
0.45 | 0.44 | 0.87 | 1.16 | |
Shareholders Equity per Share |
0.90 | 1.10 | 1.53 | 1.95 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.90 | 1.10 | 1.53 | 1.95 | |
Free Cash Flow |
(0.89) | (1.27) | (0.99) | (0.27) | |
Working Capital |
1.54 | 2.56 | 3.59 | 4.21 | |
Capital Expenditures |
0.02 | (0.02) | — | — | |
Net Current Asset Value |
(0.11) | 2.56 | 3.59 | 4.20 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
(0.02) | 0.02 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.76 | 1.10 | 1.14 | 1.38 | |
Average Payables |
0.92 | 0.68 | 0.79 | 0.89 | |
Average Inventory |
1.60 | 1.65 | 1.66 | 1.71 | |
Average Assets |
6.35 | 6.13 | 6.65 | 7.36 | |
Average Common Equity |
3.37 | 4.43 | 4.77 | 5.25 |
Columns are period end dates